Literature DB >> 20473320

The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.

Rui Huang1, Xue-Qin Chen, Ying Huang, Ni Chen, Hao Zeng.   

Abstract

The present study investigated the effects of the multikinase inhibitor sorafenib on androgen-independent cancer cells viability and intracellular signaling. Human androgen-independent PC-3 prostate cancer cells were treated with sorafenib. At concentration that suppresses extracellular signal-regulated kinase phosphorylation, sorafenib treatment reduced the mitochondrial transmembrane potential. Sorafenib also down-modulated the levels of myeloid cell leukemia 1, survivin and cellular inhibitor of apoptosis protein 2. Sorafenib induced caspase-3 cleavage and the mitochondrial release of cytochrome c. However, no nuclear translocation of apoptosis inducing factor was detected after treatment and the pan-caspase inhibitor Z-VAD-FMK had an obvious protective effect against the drug. In conclusion, sorafenib induces apoptosis through a caspase-dependent mechanism with down-regulated anti-apoptotic proteins in androgen-independent prostate cancer cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473320      PMCID: PMC3739364          DOI: 10.1038/aja.2010.21

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  39 in total

1.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

Authors:  Chunrong Yu; Laura M Bruzek; Xue Wei Meng; Gregory J Gores; Christopher A Carter; Scott H Kaufmann; Alex A Adjei
Journal:  Oncogene       Date:  2005-10-20       Impact factor: 9.867

Review 2.  Survivin study: what is the next wave?

Authors:  Fengzhi Li
Journal:  J Cell Physiol       Date:  2003-10       Impact factor: 6.384

3.  The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases.

Authors:  N Roy; Q L Deveraux; R Takahashi; G S Salvesen; J C Reed
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

4.  The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.

Authors:  David J Panka; Wei Wang; Michael B Atkins; James W Mier
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  A phase II clinical trial of sorafenib in androgen-independent prostate cancer.

Authors:  William L Dahut; Charity Scripture; Edwin Posadas; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Yunkai Yu; Liang Cao; Seth M Steinberg; Jeanny B Aragon-Ching; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

6.  Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Authors:  Jeanny B Aragon-Ching; Lokesh Jain; James L Gulley; Philip M Arlen; John J Wright; Seth M Steinberg; David Draper; Jürgen Venitz; Elizabeth Jones; Clara C Chen; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2009-01-09       Impact factor: 5.588

7.  The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.

Authors:  Mohamed Rahmani; Eric Maynard Davis; Timothy Ryan Crabtree; Joseph Reza Habibi; Tri K Nguyen; Paul Dent; Steven Grant
Journal:  Mol Cell Biol       Date:  2007-06-04       Impact factor: 4.272

Review 8.  Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death?

Authors:  Céline Candé; Francesco Cecconi; Philippe Dessen; Guido Kroemer
Journal:  J Cell Sci       Date:  2002-12-15       Impact factor: 5.285

9.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

10.  A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Authors:  S Steinbild; K Mross; A Frost; R Morant; S Gillessen; C Dittrich; D Strumberg; A Hochhaus; A-R Hanauske; L Edler; I Burkholder; M Scheulen
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640

View more
  10 in total

Review 1.  Metabolic targets for potential prostate cancer therapeutics.

Authors:  Jeffrey Twum-Ampofo; De-Xue Fu; Antonino Passaniti; Arif Hussain; M Minhaj Siddiqui
Journal:  Curr Opin Oncol       Date:  2016-05       Impact factor: 3.645

2.  Biological evaluation of a novel sorafenib analogue, t-CUPM.

Authors:  Aaron T Wecksler; Sung Hee Hwang; Jun-Yan Liu; Hiromi I Wettersten; Christophe Morisseau; Jian Wu; Robert H Weiss; Bruce D Hammock
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-21       Impact factor: 3.333

3.  Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Authors:  Aaron T Wecksler; Sung Hee Hwang; Hiromi I Wettersten; Jennifer E Gilda; Amy Patton; Leonardo J Leon; Kermit L Carraway; Aldrin V Gomes; Keith Baar; Robert H Weiss; Bruce D Hammock
Journal:  Anticancer Drugs       Date:  2014-04       Impact factor: 2.248

4.  Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Authors:  Su Jung Oh; Holger H H Erb; Alfred Hobisch; Frédéric R Santer; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2012-05-03       Impact factor: 5.678

5.  Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.

Authors:  Thomas C Wehler; Swaantje Hamdi; Annett Maderer; Claudine Graf; Ines Gockel; Irene Schmidtmann; Michael Hainz; Martin R Berger; Matthias Theobald; Peter R Galle; Markus Moehler; Carl C Schimanski
Journal:  Int J Colorectal Dis       Date:  2012-09-15       Impact factor: 2.571

6.  Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.

Authors:  Friedemann Zengerling; Wolfgang Streicher; Andres J Schrader; Mark Schrader; Bianca Nitzsche; Marcus V Cronauer; Michael Höpfner
Journal:  Int J Mol Sci       Date:  2012-09-14       Impact factor: 6.208

7.  Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.

Authors:  Joanna Jakubowicz-Gil; Ewa Langner; Dorota Bądziul; Iwona Wertel; Wojciech Rzeski
Journal:  Neurotox Res       Date:  2013-12-24       Impact factor: 3.911

8.  A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.

Authors:  Monica Archibald; Tara Pritchard; Hayley Nehoff; Rhonda J Rosengren; Khaled Greish; Sebastien Taurin
Journal:  Int J Nanomedicine       Date:  2016-01-08

9.  Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines.

Authors:  Marwa Sharaky; Marwa Kamel; Marwa A Aziz; Mervat Omran; Monira M Rageh; Khaled A M Abouzid; Samia A Shouman
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

10.  Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.

Authors:  Dhanasekhar Reddy; Ranjith Kumavath; Preetam Ghosh; Debmalya Barh
Journal:  Biomolecules       Date:  2019-11-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.